Sleep Quality and Amyloid-Beta Kinetics
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- Difference in Amyloid-beta (Abeta) Concentration in the CSF (Cerebral Spinal Fluid) of Individuals With Poor Sleep Efficiency Compared to Those With Good Sleep Efficiency as Measured by ng/ml
Study Overview
Brief Summary
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.
Detailed Description
The purpose of the study is to investigate whether or not increasing sleep efficiency will change the concentration of amyloid-beta in cerebrospinal fluid (CSF).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 45 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 45-65 years
- •Any race/ethnicity
- •Mini-Mental Status Examination score (MMSE) >=27
- •Sleep efficiency measured by actigraphy to determine good sleeper or poor sleeper
Exclusion Criteria
- •Cognitive impairment as determined by history of MMSE < 27
- •Inability to speak or understand English
- •Any sleep disorders other than insomnia
- •history of sleep-disordered breathing
- •STOP-Bang score > 3
- •History or reported symptoms suggestive of restless legs syndrome, narcolepsy or other sleep disorders
- •Sleep schedule outside the range of bedtime 8PM-12AM and wake time 4AM-9AM
- •Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery)
- •Cardiovascular disease requiring medication except for controlled hypertension (PI discretion)
- •Hepatic or renal impairment
- •Pulmonary disease (PI discretion)
- •Type 1 diabetes
- •HIV or AIDS
- •Neurologic or psychiatric disorder requiring medication (PI discretion)
- •Alcohol or tobacco use (PI discretion)
- •Use of sedating medications
- •Inability to get out of bed independently
- •Abnormal movement of the non-dominant arm (would affect actigraphy data in unpredictable ways)
- •Abnormal physical examination
- •Current pregnancy
- •History of migraine headaches (PI discretion)
- •History of drug abuse in the past 6 months
- •Urinary or fecal incontinence
- •Difficulty sleeping in an unfamiliar environment (good sleep quality group only)
- •History or presence of any clinically significant medication condition, behavioral or psychiatric condition (including suicidal ideation), or surgical history based on medical record or patient report that could affect the safety of the subject or interfere with study assessments or in the judgment of the PI is not a good candidate
Arms & Interventions
Poor sleep group treatment 1
10mg Suvorexant tablet h.s. for two consecutive nights
Intervention: Suvorexant (Drug)
Poor sleep group control
Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
Intervention: Placebo (Drug)
Good sleep group
Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
Intervention: Placebo (Drug)
Poor sleep group treatment 2
20mg Suvorexant tablet h.s. for two consecutive nights
Intervention: Suvorexant (Drug)
Outcomes
Primary Outcomes
Difference in Amyloid-beta (Abeta) Concentration in the CSF (Cerebral Spinal Fluid) of Individuals With Poor Sleep Efficiency Compared to Those With Good Sleep Efficiency as Measured by ng/ml
Time Frame: 36 hours of CSF collection
Mean difference in amyloid-beta-42 concentration between individuals with poor sleep efficiency (Poor sleep group control) compared to those with good sleep efficiency (Good sleep group)
Difference in Amyloid-beta (Abeta) Concentration in the CSF (Cerebral Spinal Fluid) of Individuals With Poor Sleep Efficiency Treated With Placebo, Suvorexant 10 mg, or Suvorexant 20 mg as Measured by ng/ml
Time Frame: 36 hours of CSF collection
Mean difference in amyloid-beta-42 concentration between individuals with poor sleep efficiency who were treated with placebo (Poor sleep group control), Suvorexant 10 mg (Poor sleep group treatment 1), and Suvorexant 20 mg (Poor sleep group treatment 2)
Secondary Outcomes
No secondary outcomes reported